

S C Bain

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1686369/s-c-bain-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114
papers

5,357
citations

25
h-index

72
g-index

131
ext. papers

7,155
ext. citations

6.8
avg, IF

5.82
L-index

#	Paper	IF	Citations
114	Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.. <i>Diabetic Medicine</i> , 2022 , e14769	3.5	0
113	Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021.. <i>Kidney International Reports</i> , 2022 , 7, 681-687	4.1	1
112	Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice.. <i>Diabetes Therapy</i> , 2022 , 13, 225	3.6	2
111	Ageing Well With Diabetes: a workshop to co-design research recommendations for improving the diabetes care of older people.. <i>Diabetic Medicine</i> , 2022 , e14795	3.5	2
110	Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently.. <i>Diabetes Therapy</i> , 2022 , 1	3.6	0
109	An elderly woman with scars on her shins.. <i>Diabetic Medicine</i> , 2022 , e14818	3.5	
108	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 64	8.7	0
107	Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials.. <i>Circulation</i> , 2021 ,	16.7	3
106	A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives. <i>Advances in Therapy</i> , 2021 , 1	4.1	4
105	Blood Glucose Responses during Cardiopulmonary Incremental Exercise Testing in Type 1 Diabetes: A Pooled Analysis. <i>Medicine and Science in Sports and Exercise</i> , 2021 , 53, 1142-1150	1.2	0
104	One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2021 , 12, 1593-1604	3.6	0
103	A retrospective epidemiological study of type 1 diabetes mellitus in wales, UK between 2008 and 2018. <i>International Journal of Population Data Science</i> , 2021 , 6, 1387	1.4	0
102	Anti-interleukin-21 antibody and liraglutide for the preservation of β cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 212-224	18.1	26
101	Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. <i>Drugs</i> , 2021 , 81, 1243-1255	5.1	1
100	Extent and prevalence of post-exercise and nocturnal hypoglycemia following peri-exercise bolus insulin adjustments in individuals with type 1 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 227-236	4.5	6
99	Costs of COVID-19 pandemic associated with diabetes in Europe: a health care cost model. <i>Current Medical Research and Opinion</i> , 2021 , 37, 27-36	2.5	11
98	The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. <i>Diabetes Therapy</i> , 2021 , 12, 143-157	3.6	41

97	Pancreatic β Cell Function Is Associated with Augmented Counterregulation to In-Exercise Hypoglycemia in Type 1 Diabetes. <i>Medicine and Science in Sports and Exercise</i> , 2021 , 53, 1326-1333	1.2	0
96	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2021 , 44, 1020-1026	14.6	7
95	Costs of the COVID-19 pandemic associated with obesity in Europe: A health-care cost model. <i>Clinical Obesity</i> , 2021 , 11, e12442	3.6	9
94	Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation. <i>Diabetic Medicine</i> , 2021 , 38, e14523	3.5	9
93	Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study. <i>Diabetes Therapy</i> , 2021 , 12, 801-811	3.6	6
92	A woman with poorly controlled type 1 diabetes and pruritic papules on her buttocks. <i>Diabetic Medicine</i> , 2021 , 38, e14539	3.5	
91	A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021 , 14, 3567-3602	3.4	18
90	Recent developments in GLP-1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23 Suppl 3, 30-39	6.7	3
89	Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population-based observational retrospective cohort study. <i>Diabetic Medicine</i> , 2021 , e14697	3.5	1
88	New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice.. <i>Drugs</i> , 2021 , 82, 97	12.1	2
87	Clumsy hands in a woman with long-standing diabetes. <i>Diabetic Medicine</i> , 2020 , 37, 1770-1771	3.5	
86	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2020 , 43, 1546-1552	14.6	38
85	The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1690-1695	6.7	7
84	Semaglutide injection for the treatment of adults with type 2 diabetes. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 675-684	3.8	3
83	A slightly itchy rash on the hand of a person with type 1 diabetes. <i>Diabetic Medicine</i> , 2020 , 37, 1609-1610	3.5	
82	The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes. <i>Diabetes Therapy</i> , 2020 , 11, 835-844	3.6	14
81	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1128-1141	15.1	25
80	Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2193-2198	6.7	5

79	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2077-2088	6.7	3
78	An unusual skin rash in a person with type 1 diabetes. <i>Diabetic Medicine</i> , 2020 , 37, 1607-1608	3.5	
77	Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020 , 13, 433-438	3.4	9
76	A man with nodules on the backs of his hands. <i>Diabetic Medicine</i> , 2020 , 37, 1766-1767	3.5	
75	Estimands in diabetes clinical trials. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 181-183	18.1	2
74	Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6). <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1339-1347	6.7	8
73	Recent advances in understanding the role of glucagon-like peptide 1. <i>F1000Research</i> , 2020 , 9,	3.6	15
72	Safety of injectable semaglutide for type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 785-798	4.1	5
71	A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes. <i>Diabetic Medicine</i> , 2020 , 37, 219-228	3.5	4
70	An update to: Pharmacological treatment for type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. <i>Diabet Med</i> 2019; 36: 1063-1071. <i>Diabetic Medicine</i> , 2020 , 37, 1405-1407	3.5	
69	Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 303-314	6.7	6
68	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 442-451	6.7	44
67	Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme. <i>Diabetes Therapy</i> , 2020 , 11, 259-277	3.6	21
66	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. <i>Cardiovascular Diabetology</i> , 2020 , 19, 156	8.7	10
65	Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2487-2492	6.7	11
64	An unusual finding during retinal screening. <i>Diabetic Medicine</i> , 2020 , 37, 1605-1606	3.5	
63	Foot deformity in a man with Type 2 diabetes. <i>Diabetic Medicine</i> , 2020 , 37, 157-158	3.5	
62	Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. <i>Journal of Medical Economics</i> , 2020 , 23, 98-105	2.4	10

61	Improved Nocturnal Glycaemia and Reduced Insulin Use Following Clinical Exercise Trial Participation in Individuals With Type 1 Diabetes. <i>Frontiers in Public Health</i> , 2020 , 8, 568832	6	
60	Effect of structured self-monitoring of blood glucose, with and without additional TeleCare support, on overall glycaemic control in non-insulin treated Type 2 diabetes: the SMBG Study, a 12-month randomized controlled trial. <i>Diabetic Medicine</i> , 2019 , 36, 578-590	3.5	12
59	Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. <i>Cardiovascular Diabetology</i> , 2019 , 18, 73	8.7	33
58	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019 , 381, 841-851	59.2	567
57	Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1745-1751	6.7	15
56	Resistance Isn't Futile: The Physiological Basis of the Health Effects of Resistance Exercise in Individuals With Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2019 , 10, 507	5.7	5
55	Sa0010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES I A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34,	4.3	1
54	FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) I A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34,	4.3	1
53	Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2450-2458	6.7	6
52	Supplementary Nitric Oxide Donors and Exercise as Potential Means to Improve Vascular Health in People with Type 1 Diabetes: Yes to NO?. <i>Nutrients</i> , 2019 , 11,	6.7	11
51	Performance of the Freestyle Libre flash glucose monitoring (flash GM) system in individuals with type 1 diabetes: A secondary outcome analysis of a randomized crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2505-2512	6.7	37
50	Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. <i>Diabetic Medicine</i> , 2019 , 36, 1063-1071	3.5	7
49	Occurrence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019 , 4, 1214-1220	16.2	20
48	Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 454-466	6.7	57
47	Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 611-621	6.7	21
46	A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA). <i>Diabetic Medicine</i> , 2019 , 36, 110-119	3.5	11
45	Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , 2019 , 170, 423-426	8	22
44	Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 499-508	6.7	54

43	A case series of DKA occurring in patients receiving treatment with SGLT-2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1800-1801	6.7	2
42	The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. <i>Diabetes Care</i> , 2018 , 41, 2229-2235	14.6	40
41	Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2018 , 12, 1079-1082	8.9	4
40	Heart rate dynamics during cardio-pulmonary exercise testing are associated with glycemic control in individuals with type 1 diabetes. <i>PLoS ONE</i> , 2018 , 13, e0194750	3.7	13
39	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , 2018 , 138, 1605-1607	16.7	20
38	Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. <i>Cardiovascular Endocrinology</i> , 2018 , 7, 18-23		3
37	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 889-897	6.7	114
36	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. <i>Circulation</i> , 2018 , 138, 2884-2894	16.7	50
35	A retrospective observational study of people with Type 1 diabetes with self-reported severe hypoglycaemia reveals high level of ambulance attendance but low levels of therapy change and specialist intervention. <i>Diabetic Medicine</i> , 2018 , 35, 1223	3.5	4
34	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. <i>Circulation</i> , 2018 , 137, 2179-2183	16.7	52
33	Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 251-260	18.1	206
32	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. <i>Lancet, The</i> , 2017 , 389, 1399-1409	40	324
31	Self-monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes (The SMBG Study): study protocol for a randomised controlled trial. <i>BMC Endocrine Disorders</i> , 2017 , 17, 4	3.3	8
30	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 275-284	18.1	180
29	Poor glycaemic control is associated with reduced exercise performance and oxygen economy during cardio-pulmonary exercise testing in people with type 1 diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2017 , 9, 93	5.6	9
28	The Cellnovo Insulin Delivery System. <i>European Endocrinology</i> , 2017 , 13, 13-16	3.4	3
27	Similar magnitude of post-exercise hyperglycemia despite manipulating resistance exercise intensity in type 1 diabetes individuals. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2016 , 26, 404-12	4.6	23
26	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 1834-1844	59.2	2547

25	Postmarket Approval Surveillance of a Low Acquisition Cost Blood Glucose Monitoring System: Assessment of the Accuracy Following ISO 15197:2013. <i>Journal of Diabetes Science and Technology</i> , 2016 , 10, 1195-6	4.1	2
24	Algorithm that delivers an individualized rapid-acting insulin dose after morning resistance exercise counters post-exercise hyperglycaemia in people with Type 1 diabetes. <i>Diabetic Medicine</i> , 2016 , 33, 506-10	3.5	25
23	LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. <i>Cardiovascular Diabetology</i> , 2016 , 15, 29	8.7	33
22	Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation. <i>PLoS ONE</i> , 2016 , 11, e0154229	3.7	10
21	Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 1157-1166	6.7	15
20	Omarigliptin for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1947-52	4	14
19	Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 196-9	6.7	17
18	Changes in plasma levels of N-arachidonoyl ethanolamine and N-palmitoylethanolamine following bariatric surgery in morbidly obese females with impaired glucose homeostasis. <i>Journal of Diabetes Research</i> , 2015 , 2015, 680867	3.9	18
17	IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy. <i>Diabetes Therapy</i> , 2015 , 6, 573-591	3.6	24
16	The new NICE guidelines for type 2 diabetes – a critical analysis. <i>British Journal of Diabetes and Vascular Disease</i> , 2015 , 15, 3		10
15	ADP-ribosylation factor 6 regulates endothelin-1-induced lipolysis in adipocytes. <i>Biochemical Pharmacology</i> , 2014 , 90, 406-13	6	17
14	The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist. <i>Diabetes Therapy</i> , 2014 , 5, 367-83	3.6	19
13	Metabolic implications when employing heavy pre- and post-exercise rapid-acting insulin reductions to prevent hypoglycaemia in type 1 diabetes patients: a randomised clinical trial. <i>PLoS ONE</i> , 2014 , 9, e97143	3.7	26
12	Large pre- and postexercise rapid-acting insulin reductions preserve glycemia and prevent early- but not late-onset hypoglycemia in patients with type 1 diabetes. <i>Diabetes Care</i> , 2013 , 36, 2217-24	14.6	51
11	One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. <i>Journal of Diabetes and Its Complications</i> , 2013 , 27, 492-500	3.2	35
10	Liraglutide in Combination with Metformin or Sulfonylurea for the Treatment of Type 2 Diabetes in Adult patients. <i>Clinical Medicine Insights Therapeutics</i> , 2012 , 4, CMT.S7283	0	
9	Impact of pre-exercise rapid-acting insulin reductions on ketogenesis following running in Type 1 diabetes. <i>Diabetic Medicine</i> , 2011 , 28, 218-22	3.5	26
8	A combined insulin reduction and carbohydrate feeding strategy 30 min before running best preserves blood glucose concentration after exercise through improved fuel oxidation in type 1 diabetes mellitus. <i>Journal of Sports Sciences</i> , 2011 , 29, 279-89	3.6	47

7	Diabetes, diabetes therapies and cancer: what's the link?. <i>British Journal of Diabetes and Vascular Disease</i> , 2011 , 11, 235-238		5
6	Clinical experience with liraglutide. <i>International Journal of Clinical Practice</i> , 2010 , 64, 44-8	2.9	4
5	Blood glucose responses to reductions in pre-exercise rapid-acting insulin for 24 h after running in individuals with type 1 diabetes. <i>Journal of Sports Sciences</i> , 2010 , 28, 781-8	3.6	30
4	Treatment of type 2 diabetes mellitus with orally administered agents: advances in combination therapy. <i>Endocrine Practice</i> , 2009 , 15, 750-62	3.2	4
3	Safety and side effects of the insulin analogues. <i>Expert Opinion on Drug Safety</i> , 2006 , 5, 131-43	4.1	16
2	Safety and side effects of the insulin analogues. <i>Expert Opinion on Drug Safety</i> , 2006 , 5, 349-50	4.1	
1	Complex disease genetics enters the high street. <i>European Journal of Clinical Investigation</i> , 2003 , 33, 186-8	4.6	